Abstract: The invention relates to computer-based methods, systems, and mediums for identifying a change to the cumulative characterization of certain brain performance data collected from an individual, wherein the collected brain performance data is directly related to how at least one of the individual's neuromotor or cognitive brain functions is performing, hereinafter such a cumulative characterization is referred to as the individual's “Brain Profile”.

Abstract: The invention relates to computer-based methods, systems, and mediums for identifying a change to the cumulative characterization of certain brain performance data collected from an individual, wherein the collected brain performance data is directly related to how at least one of the individual's neuromotor or cognitive brain functions is performing, hereinafter such a cumulative characterization is referred to as the individual's “Brain Performance Profile”.

Abstract: Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in the elderly whose etiology remains largely unknown. Previous studies identified chromosome 1q32 as harboring a susceptibility locus for AMD, but it was not identified. We identified a strongly associated haplotype in two independent data sets. DNA sequencing of the complement factor II gene (CFII) within this haplotype revealed a coding variant, Y402II, that significantly increases the risk for AMD with odds ratios between 2.45 and 5.57. This identifies Complement factor II as involved in pathogenesis of AMD. This single variant alone is so common that it likely explains 43 percent of AMD in older adults. In addition, we have replicated and refined previous reports implicating a coding change in LOC387715 as the second major AMD susceptibility allele. The effect of rs10490924 appears to be completely independent of the Y402H variant in the CFH gene.

Abstract: Age-related macular degeneration (AMD) is a leading cause of visual impairment and blindness in the elderly whose etiology remains largely unknown. Previous studies identified chromosome 1q32 as harboring a susceptibility locus for AMD, but it was not identified. We identified a strongly associated haplotype in two independent data sets. DNA sequencing of the complement factor II gene (CHI) within this haplotype revealed a coding variant, Y402II, that significantly increases the risk for AMD with odds ratios between 2.45 and 5.57. This identifies Complement factor II as involved in pathogenesis of AMD. This single variant alone is so common that it likely explains 43 percent of AMD in older adults. In addition, we have replicated and refined previous reports implicating a coding change in LOC387715 as the second major AMD susceptibility allele. The effect of rs10490924 appears to be completely independent of the Y402II variant in the CFH gene.

Abstract: The present invention provides methods and compositions for screening a subject for Parkinson disease, for increased risk of developing Parkinson disease and/or for an earlier or later age of developing Parkinson disease, comprising detecting the presence of a genetic marker associated with Parkinson disease.

Abstract: The present invention provides improved adenovirus vectors and packaging cell lines. One type of improved adenoviral vector comprises deletions within the E2b region of the adenoviral genome. These E2b-deleted virus are used in conjunction with novel cell lines that constitutively express E2b gene products. The present invention further provides adenoviral vectors deleted for all viral coding regions. These “gutted” vectors permit the transfer of large genes to cells as demonstrated herein by the transfer of the dystrophin gene to the muscle of mice. The E2b-deleted vectors and the gutted vectors provide improved adenoviral vectors useful for a wide variety of gene therapy applications.

Abstract: A lightweight baseball base having gently inclined edges and an elastomeric filler material. The top of the base has a lateral dimension of between 50% to 65% of the total base lateral dimension, with the remainder equally divided between opposed inclined edges. The elastomeric filler is a shaped foam pad with a non-porous cover. The cover is fastened to a bottom support plate which has a tubular sleeve extending therefrom for anchoring the base.